Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis

Published:2017-05-31 Issue:35 Volume:8 Page:59901-59914
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wang Xiaohui¹²,Bao Zhengqiang¹²,Zhang Xiaoju³,Li Fei¹,Lai Tianwen¹,Cao Chao¹,Chen Zhihua¹,Li Wen¹,Shen Huahao¹⁴,Ying Songmin¹²

Affiliation:

1. Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China

2. Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China

3. Department of Respiratory Medicine, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China

4. State Key Laboratory of Respiratory Diseases, Guangzhou, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The World of Immunotherapy Needs More Than PD-1/PD-L1—Two of the New Kids on the Block: LAG-3 and TIGIT;Onco;2024-07-01

2. Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells;Nature Communications;2023-05-05

3. Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis;Expert Review of Anticancer Therapy;2023-03-01

4. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition;Therapeutic Advances in Medical Oncology;2023-01

5. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction;Bioorganic & Medicinal Chemistry;2022-11